These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. A Phase I study of infusional vinblastine in combination with the P-glycoprotein antagonist PSC 833 (valspodar). Bates S; Kang M; Meadows B; Bakke S; Choyke P; Merino M; Goldspiel B; Chico I; Smith T; Chen C; Robey R; Bergan R; Figg WD; Fojo T Cancer; 2001 Sep; 92(6):1577-90. PubMed ID: 11745237 [TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetic study of infusional valspodar. Ma MK; McLeod HL; Westervelt P; Fracasso PM J Clin Pharmacol; 2002 Apr; 42(4):412-8. PubMed ID: 11936566 [TBL] [Abstract][Full Text] [Related]
25. Influence of the interval between the administration of doxorubicin and paclitaxel on the pharmacokinetics of these drugs in patients with locally advanced breast cancer. Moreira A; Lobato R; Morais J; Silva S; Ribeiro J; Figueira A; Vale D; Sousa C; Araújo F; Fernandes A; Oliveira J; Passos-Coelho JL Cancer Chemother Pharmacol; 2001 Oct; 48(4):333-7. PubMed ID: 11710635 [TBL] [Abstract][Full Text] [Related]
26. Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group study. Fracasso PM; Brady MF; Moore DH; Walker JL; Rose PG; Letvak L; Grogan TM; McGuire WP J Clin Oncol; 2001 Jun; 19(12):2975-82. PubMed ID: 11408492 [TBL] [Abstract][Full Text] [Related]
27. A phase I/II study of infusional vinblastine with the P-glycoprotein antagonist valspodar (PSC 833) in renal cell carcinoma. Bates SE; Bakke S; Kang M; Robey RW; Zhai S; Thambi P; Chen CC; Patil S; Smith T; Steinberg SM; Merino M; Goldspiel B; Meadows B; Stein WD; Choyke P; Balis F; Figg WD; Fojo T Clin Cancer Res; 2004 Jul; 10(14):4724-33. PubMed ID: 15269145 [TBL] [Abstract][Full Text] [Related]
28. A phase I trial of liposomal doxorubicin, paclitaxel and valspodar (PSC-833), an inhibitor of multidrug resistance. Advani R; Lum BL; Fisher GA; Halsey J; Chin DL; Jacobs CD; Sikic BI Ann Oncol; 2005 Dec; 16(12):1968-73. PubMed ID: 16126736 [TBL] [Abstract][Full Text] [Related]
29. Phase I study of paclitaxel by three-hour infusion: hypotension just after infusion is one of the major dose-limiting toxicities. Tamura T; Sasaki Y; Nishiwaki Y; Saijo N Jpn J Cancer Res; 1995 Dec; 86(12):1203-9. PubMed ID: 8636011 [TBL] [Abstract][Full Text] [Related]
30. The pharmacokinetics and pharmacodynamics of high-dose paclitaxel monotherapy (825 mg/m2 continuous infusion over 24 h) with hematopoietic support in women with metastatic breast cancer. Papadopoulos KP; Egorin MJ; Huang M; Troxel AB; Kaufman E; Balmaceda CM; Vahdat LT; Hesdorffer CS Cancer Chemother Pharmacol; 2001; 47(1):45-50. PubMed ID: 11221961 [TBL] [Abstract][Full Text] [Related]
31. Longitudinal assessment of a P-glycoprotein-mediated drug interaction of valspodar on digoxin. Kovarik JM; Rigaudy L; Guerret M; Gerbeau C; Rost KL Clin Pharmacol Ther; 1999 Oct; 66(4):391-400. PubMed ID: 10546923 [TBL] [Abstract][Full Text] [Related]
32. Phase I crossover study of paclitaxel with r-verapamil in patients with metastatic breast cancer. Tolcher AW; Cowan KH; Solomon D; Ognibene F; Goldspiel B; Chang R; Noone MH; Denicoff AM; Barnes CS; Gossard MR; Fetsch PA; Berg SL; Balis FM; Venzon DJ; O'Shaughnessy JA J Clin Oncol; 1996 Apr; 14(4):1173-84. PubMed ID: 8648372 [TBL] [Abstract][Full Text] [Related]
33. Phase I study of valspodar (PSC-833) with mitoxantrone and etoposide in refractory and relapsed pediatric acute leukemia: a report from the Children's Oncology Group. O'Brien MM; Lacayo NJ; Lum BL; Kshirsagar S; Buck S; Ravindranath Y; Bernstein M; Weinstein H; Chang MN; Arceci RJ; Sikic BI; Dahl GV Pediatr Blood Cancer; 2010 May; 54(5):694-702. PubMed ID: 20209646 [TBL] [Abstract][Full Text] [Related]
34. Intracellular levels of two cyclosporin derivatives valspodar (PSC 833) and cyclosporin a closely associated with multidrug resistance-modulating activity in sublines of human colorectal adenocarcinoma HCT-15. Uchiyama-Kokubu N; Watanabe T; Cohen D Jpn J Cancer Res; 2001 Oct; 92(10):1116-26. PubMed ID: 11676863 [TBL] [Abstract][Full Text] [Related]
35. Altered pharmacokinetics of paclitaxel by the concomitant use of morin in rats. Choi BC; Choi JS; Han HK Int J Pharm; 2006 Oct; 323(1-2):81-5. PubMed ID: 16806758 [TBL] [Abstract][Full Text] [Related]
36. The multidrug resistance modulator valspodar (PSC 833) is metabolized by human cytochrome P450 3A. Implications for drug-drug interactions and pharmacological activity of the main metabolite. Fischer V; Rodríguez-Gascón A; Heitz F; Tynes R; Hauck C; Cohen D; Vickers AE Drug Metab Dispos; 1998 Aug; 26(8):802-11. PubMed ID: 9698296 [TBL] [Abstract][Full Text] [Related]
37. Oral bioavailability of a novel paclitaxel formulation (Genetaxyl) administered with cyclosporin A in cancer patients. Chu Z; Chen JS; Liau CT; Wang HM; Lin YC; Yang MH; Chen PM; Gardner ER; Figg WD; Sparreboom A Anticancer Drugs; 2008 Mar; 19(3):275-81. PubMed ID: 18510173 [TBL] [Abstract][Full Text] [Related]
39. Role of specific apoptotic pathways in the restoration of paclitaxel-induced apoptosis by valspodar in doxorubicin-resistant MCF-7 breast cancer cells. Chadderton A; Villeneuve DJ; Gluck S; Kirwan-Rhude AF; Gannon BR; Blais DE; Parissenti AM Breast Cancer Res Treat; 2000 Feb; 59(3):231-44. PubMed ID: 10832593 [TBL] [Abstract][Full Text] [Related]
40. Altered clearance of unbound paclitaxel in elderly patients with metastatic breast cancer. Smorenburg CH; ten Tije AJ; Verweij J; Bontenbal M; Mross K; van Zomeren DM; Seynaeve C; Sparreboom A Eur J Cancer; 2003 Jan; 39(2):196-202. PubMed ID: 12509952 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]